New York, New York–(Newsfile Corp. – July 13, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between…Read More
You might also be interested in reading Newmark targets $630M adjusted EBITDA by 2026 amid growth in market share and business lines.